1. Home
  2. AMST vs MBAI Comparison

AMST vs MBAI Comparison

Compare AMST & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amesite Inc.

AMST

Amesite Inc.

HOLD

Current Price

$1.80

Market Cap

9.2M

Sector

Technology

ML Signal

HOLD

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.62

Market Cap

10.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
AMST
MBAI
Founded
2017
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
9.2M
10.6M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
AMST
MBAI
Price
$1.80
$1.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
46.0K
161.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
40.46
N/A
EPS
N/A
N/A
Revenue
$110,459.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.57
$1.31
52 Week High
$4.78
$3.92

Technical Indicators

Market Signals
Indicator
AMST
MBAI
Relative Strength Index (RSI) 41.76 47.23
Support Level N/A $1.31
Resistance Level $2.15 $1.87
Average True Range (ATR) 0.13 0.16
MACD 0.00 -0.02
Stochastic Oscillator 40.35 33.49

Price Performance

Historical Comparison
AMST
MBAI

About AMST Amesite Inc.

Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: